鋅 Zinc × 年齡相關性黃斑部病變（AMD）
結論：證據不足
獨立判讀為 Tier B（強且一致的證據，限定族群）— 接近 Tier A 但保留下列 caveats 不滿。
D 🔴 D 反證據 證據不足 ⚠️ medium — moderate promotional content
獨立判讀為 Tier B（強且一致的證據，限定族群）— 接近 Tier A 但保留下列 caveats 不滿。
理由：(1) RCT 基礎堅實 — AREDS landmark trial（NEI 主導、樣本大、長期追蹤）於 2001 年確立 25% 相對風險下降，AREDS2（2013）以 lutein/zeaxanthin 取代 β-胡蘿蔔素並驗證 25 mg 與 80 mg 鋅效益相當，AREDS2 Report 28（2022）以 10 年追蹤再次確認；(2) Cochrane 2023 Evans & Lawrenson 系統回顧 26 RCT 11,952 人，鋅進展為晚期 AMD OR 0.83 [0.70-0.98] 中等確定性、新生血管型 OR 0.76 [0.62-0.93] 中等確定性 — 兩個關鍵終點均統計顯著；(3) Csader 2022 SR/MA（n=5,634）獨立確認 advanced AMD OR 0.72 (99% CI 0.52-0.98)；(4) Li 2022 network MA（n=85,321）顯示鋅視力改善排名第一；(5) Keenan 2024 post-hoc 顯示含鋅配方延緩 GA 向中央凹推進 HR ~0.45 p<.001 — 即使在 atrophic 進展端也有明確訊號；(6) AAO 2019 Preferred Practice Pattern 將 AREDS2（含 80 mg 鋅）列為 Level I 證據建議用於中度 AMD 或單眼晚期 AMD；(7) 五大 L5 來源（NIH ODS supportive / Mayo supportive 限定中度至晚期 / Cleveland conditionally_supportive / Harvard supportive 限定中度乾性或單眼晚期 / AAO supportive Level A）方向完全一致無分歧。
未達 Tier A 之保留：(a) 鋅效應主要來自 AREDS landmark trial 及其延伸，獨立 zinc-only RCT 少；(b) 對 GA-only 終點 Cochrane 2023 OR 0.84 [0.64-1.10] 未達顯著；(c) 早期 AMD 與一般預防無效；(d) 80 mg/日超過 UL 40 mg/日，須與銅同服、有 GU 副作用；(e) Examine 不單列鋅 AMD（採配方歸類）。
整體仍為 SAMS/general 任何 condition 中最強的 publish 案例之一。
⚖️
評分透明度
所有分數由 7 層證據引擎計算，過程公開可查原始分數 0.74
D
C
B
A
S
← 反證據 / 無效有效 / 強證據 →
最終評級
D · 證據不足
信心度
78%
證據方向大致一致
證據層級
E1
Cochrane 高品質系統性回顧／統合分析
▸查看完整決策路徑（audit trail）
- compute_raw_score — 加權公式: L2×0.30 + L3×0.25 + L5×0.25 + L11×0.10 + L1×0.10 = 0.745
- tier_from_score — 依分數區間映射至 tier letter
- apply_hec_rules — 高品質 SR/MA 顯示 negative 主導 (2 negative > 1 positive)，下層 RCT 不能推翻
- apply_hec_override — HEC-1 高階證據 negative — 強制由 A 改為 D
- tier_strict_requirement_check — Tier 條件達標，未降階
- detect_disputes — 偵測到 0 個 hard + 0 個 soft dispute
- decide_status — 依 tier + dispute 結果決定 status
Long-term Outcomes of Adding Lutein/Zeaxanthin and Omega-3 Fatty Acids to the AREDS Supplements on Age-Related Macular Degeneration Progression: AREDS2 Report 28
結論：In 6,351 eyes from 3,882 participants over 10-year follow-up, lutein/zeaxanthin substitution for beta-carotene reduced progression to late AMD (HR 0.85, 95% CI 0.73-0.98, P=.02); secondary zinc dose comparison (80 mg vs 25 mg) showed no statistically significant difference in progression to late AMD (HR 1.04, 95% CI 0.94-1.14, P=.48); beta-carotene increased lung cancer risk in former smokers (HR 1.82, 95% CI 1.06-3.12); NEI continues to recommend the AREDS2 formulation including 80 mg zinc
前往 PubMed
Antioxidant vitamin and mineral supplements for slowing the progression of age-related macular degeneration (Cochrane Database Syst Rev, Evans & Lawrenson)
結論：Across 26 RCTs (11,952 participants), zinc supplementation probably reduces progression to late AMD over 6 years (OR 0.83, 95% CI 0.70-0.98; 3 studies, 3,790 participants; moderate-certainty evidence); reduces progression to neovascular AMD (OR 0.76, 95% CI 0.62-0.93; moderate-certainty); non-significant effect on geographic atrophy (OR 0.84, 95% CI 0.64-1.10); borderline effect on visual loss (OR 0.87, 95% CI 0.75-1.00; 2 studies, 3,791 participants); GI symptoms and (in AREDS) genitourinary problems in men were the main adverse effects
前往 PubMed
The Effect of Dietary Supplementations on Delaying the Progression of Age-Related Macular Degeneration: A Systematic Review and Meta-Analysis (Csader et al., Nutrients)
結論：Across 20 included studies (8 in meta-analysis), zinc-containing supplementation slowed AMD progression; AREDS antioxidants + zinc arm showed OR 0.72 (99% CI 0.52-0.98) for progression to advanced AMD vs placebo (~25% relative risk reduction over 6 years); pooled analyses also supported lutein/zeaxanthin and omega-3; authors conclude AREDS-style supplementation including zinc is the most consistently effective dietary intervention to delay AMD progression in intermediate AMD
前往 PubMed
Efficacy of different nutrients in age-related macular degeneration: A systematic review and network meta-analysis (Li et al., Semin Ophthalmol)
結論：Across 13 RCTs (85,321 participants) in network meta-analysis, zinc and carotenoids ranked first and second for improving visual acuity in established AMD; beta-carotene ranked best for preventing progression to late AMD; multivitamins alone did not prevent late AMD development; zinc demonstrated favorable surface-under-cumulative-ranking-curve (SUCRA) for visual acuity outcomes; specific HR/OR for zinc-only progression to late AMD not separately pooled in network
前往 PubMed
Oral Antioxidant and Lutein/Zeaxanthin Supplements Slow Geographic Atrophy Progression to the Fovea in Age-Related Macular Degeneration (Keenan et al., Ophthalmology - AREDS/AREDS2 secondary analysis)
結論：In eyes with non-central GA (392 from AREDS, 313 from AREDS2), AREDS/AREDS2 supplementation including zinc significantly slowed proximity progression of GA toward fovea: AREDS antioxidants+zinc reduced GA-to-fovea progression rate vs placebo (HR ~0.45, P<.001 for AREDS arm); AREDS2 lutein/zeaxanthin + zinc continued the effect; zinc remained part of the active formulation throughout, supporting zinc retention in long-term AREDS2 protocol; no significant difference between 25 mg and 80 mg zinc within AREDS2 secondary randomization for this endpoint
前往 PubMed
L4a US FDA
中性
— 本適應症無對應資料
L4b EU EFSA
支持
contributes to normal function of the immune system 來源↗
L4c UK NHS
謹慎
You should be able to get all the zinc you need from your daily diet 來源↗
L4d TW TFDA / 衛福部
支持
鋅之每日最高攝食量不得超過30 mg 來源↗
L4e WHO
支持
zinc has been recommended by WHO and UNICEF as the only treatment to be coupled with oral rehydration salts for the treatment of all diarrhoea episodes 來源↗
L5a NIH Office of Dietary Supplements
支持
Zinc is an essential mineral involved in numerous aspects of cellular metabolism 來源↗
L5b Mayo Clinic
支持
concentrated in the retina 來源↗
L5c Cleveland Clinic
謹慎
Studies suggest that taking 80 milligrams (mg) of a zinc supplement, along with other vitamins for eye health, can lower the risk of advanced age-related macular degeneration (AMD) and vision loss by 25%. 來源↗
L5d Harvard Health
支持
80 mg of zinc as zinc oxide 來源↗
L5e Specialty Society (condition-mapped)
支持
AREDS2 formulation for intermediate or advanced AMD 來源↗
PTT · Dcard · Mobile01 彙整自公開論壇討論，非統計抽樣，僅反映社群風向。
廣告 / 業配密度 中度
低中高
📍立場總覽
台灣社群幾乎不把「鋅」當成單獨護眼成分討論，鋅僅作為 AREDS/AREDS2 複方（葉黃素+玉米黃素+維C+維E+鋅+銅）的配角出現。討論主軸壓倒性集中在葉黃素，鄉民在 regimen/Health/Laser_eye 版多在問「葉黃素哪牌好」，鋅只被列在成分表內、少有人單獨評論其療效或劑量。AMD 患者導向的醫療級複方以博士倫 PreserVision AREDS2 最常被點名，但相關討論多偏代購/開箱，業配與商業氣味偏濃。
💬社群實感
無共識（鋅單獨用於黃斑部幾乎無台灣社群實測心得；相關討論絕大多數聚焦葉黃素複方，鋅僅作為 AREDS 配方成分被列出，個別使用者難以分辨鋅本身的效果）
破解迷思 社群最常見的 4 個誤解
✓
事實把「護眼」直接等同於「補葉黃素」，忽略 AREDS 證據其實是含鋅+銅+抗氧化維生素的整套複方，鋅單吃≠AREDS效果
✕
迷思誤以為任何含鋅的綜合葉黃素都等於 AREDS2 醫療配方
✓
事實多數市售葉黃素鋅含量遠低於 AREDS2 規格，劑量不對等
✓
事實忽略高劑量鋅需配銅：社群很少提到長期單補高劑量鋅會誘發缺銅性貧血/神經病變，AREDS 加 2mg 銅正是為此
✕
迷思把『預防』與『逆轉』混為一談
✓
事實AREDS 配方（含鋅）是延緩中晚期 AMD 惡化，並非逆轉或治癒已成形的黃斑部病變
🩹 社群通報的副作用
- 台灣社群幾乎無「鋅用於黃斑部」的直接副作用回報（因少有人單獨補鋅護眼）
- 一般性提醒（非眼科專屬）：空腹補鋅易反胃噁心，長期高劑量鋅可能導致缺銅
🏷️ 社群熱議品牌
依論壇被提及頻率，非銷售或品質排序。
- 博士倫 PreserVision AREDS2（醫療級、AMD 患者導向最常被點名，多為美國代購/iHerb）
- 三多葉黃素（成分含鋅、硒，CP 值取向）
- DHC 葉黃素（日本代購、便宜）
- 明守對策、樂敦、營養師輕食（一般護眼葉黃素複方，鋅為配料）
⚠️ 列出僅代表「TW 社群討論度高」，不代表本站推薦或背書。本站不販售任何產品、無導購連結。
- 戒菸
- 地中海飲食
- 抗血管內皮生長因子（anti-VEGF）眼內注射
查看 ClaimReview 結構化資料 (JSON-LD)
{
"@context": "https://schema.org",
"@type": "ClaimReview",
"url": "https://gpt-dict.com/claim/CLM-COND-amd-INT-zinc-001/",
"datePublished": "2026-06-01",
"author": {
"@type": "Organization",
"name": "gpt-dict.com",
"url": "https://gpt-dict.com"
},
"claimReviewed": "鋅能改善年齡相關性黃斑部病變（AMD）",
"inLanguage": "zh-TW",
"itemReviewed": {
"@type": "Claim",
"appearance": []
},
"reviewRating": {
"@type": "Rating",
"ratingValue": 1,
"bestRating": 5,
"worstRating": 1,
"alternateName": "🔴 D 反證據"
}
}